Home
Biotron Limited
ASX Code
BIT
Sector
Pharmaceuticals- Biotechnology & Life Sciences
Investor Centre
https://www.biotron.com.au/investor-centre/
Website
https://www.biotron.com.au/
About
Biotron Limited – Developing a new class of antiviral therapies
Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.
News
Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy |